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Interleukin-6 (IL-6) was found to be a growth factor of renal cell carcinomas. Furthermore, renal cell carcinomas freshly 
isolated from the patients expressed mRNA of IL-6 and secreted biologically active IL-6 under the culture conditions 
where the tumor cells could grow, but they did not produce IL-6 nor proliferate in the absence of fetal calf serum. The 
production of IL-6 by the tumor cells was also demonstrated by immunostaining of the IL-6-producing cells utilizing 
anti-IL-6 antiserum. Moreover, anti-IL-6 antiserum specifically inhibited the in vitro tumor growth. All data indicated 
that IL-6 functions as an in vitro autocrine growth factor of renal cell carcinomas. 
Interleukin-6; Autocrine growth factor; (Renal cell carcinoma) 
1. INTRODUCTION 
Interleukind (IL-6) is a cytokine acting on a 
variety of cells including lymphocytes, 
hepatocytes, haematopoietic stem cells and nerve 
cells as either a growth factor, a growth inhibitor or 
a differentiation inducing factor [1,2]. Further- 
more, IL-6 was demonstrated to be a growth factor 
for plasmacytoma, myeloma and certain T cell 
lymphoma cells [3-51 and was suggested to be in- 
volved in the oncogenesis of these tumors [2]. Since 
IL-6 is produced by a variety of cells and acts as a 
growth factor for various kinds of cells, there is the 
possibility that IL-6 acts as a growth factor for the 
other kinds of tumor and is involved in the on- 
cogenesis of those tumors. 
Certain patients with renal cell carcinoma show 
fever, an increase in serum acute phase proteins, 
secondary amyloidosis, hepatic disorder and 
leukemoid reactions [6,7], suggesting that tumor 
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cells may produce substances which can induce 
acute phase protein synthesis. Since IL-6 was 
found to be a major factor which regulates the 
biosynthesis of acute phase proteins in hepatocytes 
[8-lo], it was examined whether IL-6 is produced 
by renal cell carcinoma cells and acts as their own 
growth factor. In this report, we show that IL-6 
functions as an autocrine growth factor for renal 
cell carcinomas in vitro. 
2. MATERIALS AND METHODS 
2. I. Reagents 
Recombinant IL-6 was produced in E. coli as described 
previously 111,121. Goat anti-IL-6 antiserum was made by im- 
munizing recombinant IL-6, and was kindly provided by Dr 
Poole, National Biological Standards Board, WHO. Mono- 
clonal antibody, K 2.7 specific to renal cell carcinoma 1131 was 
a kind gift from Dr Kinouchi, The Center of Adult Diseases, 
Osaka, Japan. Monoclonal antibody, M206, specific to 
macrophages was described previously [14]. 
2.2. Cells and culture conditions 
Renal cell carcinoma cell line, ACHN, was obtained from the 
ATCC (Maryland, USA). The tumor mass obtained from the 
patients with renal cell carcinoma was minced and trypsinized to 
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obtain single cell suspension. These cells were cultured in RPM1 
1640 containing 10% fetal calf serum (FCS) (Flow Laboratories 
Inc., USA). The spindle shaped cells were eradicated by needle 
puncture. Adherent cells were harvested after treatment with 
0.25% trypsin and 0.02% EDTA and used as renal cell car- 
cinoma cells. 
2.3. Determination of IL-6 activity 
IL-6 activity was examined utilizing the IL-B-dependent 
murine hybridoma, MH60.BSF2, as described previously [ 151. 
2.4. Northern blot analysis 
RNA was purified by the guanidine method and subjected to 
Northern blot analysis utilizing ‘2P-labeled Taql-Ban11 frag- 
ment of pBSF2.38 insert cDNA as described previously 111). 
2.5. Immunostaining of renal cell carcinoma cells 
Renal cell carcinoma cells were stained with anti-renal cell 
carcinoma antibody (K 2.7) and fluorescence-conjugated anti- 
mouse IgG (Tago, Inc.). IL-dproducing cells fixed in cold 
acetone were stained with goat anti-human IL-6 antiserum 
utilizing the avidin-biotin-peroxidase complex method (E.Y. 
Laboratories, Inc.) [16]. Goat anti-human IgG antiserum was 
used as a control antibody. 
3. RESULTS AND DISCUSSION 
Renal cell carcinoma cells freshly isolated from 
patients were found not to grow well in the culture 
medium without FCS. It was examined whether 
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Fig. 1. IL-6-induced cell growth of renal cell carcinoma cells 
isolated from the patients. Tumor cells (4 x l@/well) were 
cultured in the presence or absence of 20 ng/ml recombinant 
IL-6 without FCS. They were also cultured in the presence of 
10% FCS without IL-6. After 6 days, the number of recovered 
cells was determined. Data represents the percent increase of cell 
number and the mean f SE of triplicate cultures. 
IL-6 can induce in vitro cell growth of renal cell 
carcinomas in the absence of FCS. IL-6 induced in 
vitro cell growth of renal cell carcinoma cells 
freshly isolated from all 18 patients. In 13 cases, 
the cell growth induced by IL-6 was almost 
equivalent o that induced by 10% FCS and in the 
other cases, it was approx. 50% of that exerted by 
10% FCS. Fig.1 demonstrates representative data 
on 3 different renal cell carcinoma cells. To 
demonstrate whether the responding cells are in 
fact renal cell carcinoma cells, the growing cells 
were stained with periodic acid-Schiff (PAS) and 
monoclonal anti-renal cell carcinoma antibody, 
K2.7. Almost all cells were positively stained (not 
shown). The direct action of IL-6 was further con- 
firmed, because IL-6 induced cell growth of the 
renal cell carcinoma cell line, ACHN (not shown). 
IL-6 could replace the requirement for FCS in in 
vitro growth of renal cell carcinoma. Therefore, 
the possibility was examined whether FCS might 
induce IL-6 production in renal cell carcinoma 
cells. IL-6 activities equivalent o those exerted by 
1-15 ng/ml of recombinant IL-6 were detected in 
the culture supernatants of ACHN cell line or 
freshly isolated renal cell carcinoma cells cultured 
in the presence of 10% FCS but not in the absence 
of FCS. The IL-6 activity was neutralized by goat 
anti-IL-6 antiserum (not shown). The amount of 
IL-6 in the culture supernatants was not changed 
by the treatment of the cell preparation with anti- 
macrophage monoclonal antibody, M206 and com- 
plement (not shown). Furthermore, ILd-producing 
cells were directly identified by immunostaining 
Fig.2. lmmunostaining of cytoplasmic IL-6 in renal cell 
carcinoma cells. 
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utilizing goat anti-IL-6 antiserum. As shown in 
fig.2, approx. 2-9% of cultured renal cell car- 
cinoma cells were positively stained by anti-IL-6 
antiserum. The staining was inhibited by the 
presence of 20 ,ug/ml of recombinant IL-6, in- 
dicating the specificity of the staining. Moreover, 
IL-6 mRNA was detected in RNA preparations 
isolated from renal cell carcinoma cells cultured in 
the presence of 1OVo FCS for 2 days (fig.3a) or 
ACHN cell line (fig.3b). 
As described, growing renal cell carcinoma cells 
produced IL-6 in the presence of 10% FCS, 
whereas they did not proliferate nor produce IL-6 
in the absence of FCS. The data suggest that IL-6 
functions as an autocrine growth factor of renal 
cell carcinoma cells in vitro. To prove this possibili- 
ty, it was examined whether anti-IL-6 antibodies 
can inhibit the cell growth of renal cell carcinoma 
cells in the presence of FCS. As shown in fig.4, 
goat anti-IL-6 antiserum inhibited the cell growth 
of renal cell carcinoma cells isolated from 2 pa- 
tients in a dose-dependent manner, but control 
goat anti-human IgG antiserum did not. The in- 
Fig.3. Expression of IL-6 mRNA in renal cell carcinoma cells 
obtained from the patients (a) and ACHN cell line (b). 
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Fig.4. Inhibitory effect of anti-IL-6 antiserum on the in vitro 
growth of renal cell carcinoma cells. Tumor cells isolated from 
two patients were cultured (4 x l@/well) in the presence of 
10% FCS with various concentrations of goat anti-human IL-6 
antiserum (0, 0) or goat anti-human IgG antiserum (m, 0) for 
6 days. (A, A) data on the culture containing both goat anti- 
IL-6 antiserum (200-fold dilution) and 20 ng/ml of recombinant 
IL-6. Data represents the mean of triplicate cultures. 
hibitory effect of anti-IL-6 antiserum was specific 
for IL-6, because the addition of 20 ng/ml of 
recombinant IL-6 could recover the anti-IL-6- 
induced inhibition of tumor growth as shown in 
fig.4. 
Since Sporn and Todaro [17] proposed the 
autocrine stimulation as a mechanism of transfor- 
mation, circumstantial evidence has been ac- 
cumulating to support the original hypothesis in a 
variety of growth factors and tumors [ 181. We also 
demonstrated previously that IL-6 is an autocrine 
growth factor for human myeloma cells [4]. 
Therefore, this is another example of IL-6-mediated 
autocrine growth loop operating in renal cell car- 
cinoma. 
At present, it is not known whether IL-6 is ac- 
tually produced by renal cell carcinoma cells in 
vivo. However, certain patients with aggressive 
type of renal cell carcinoma show an increase in 
serum acute phase proteins [6,7], suggesting that 
these rapidly growing renal cell carcinoma cells 
produce IL-6 in vivo also, because IL-6 is a major 
factor regulating acute phase protein biosynthesis 
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[&lo]. It remains to be elucidated what stimuli can 
induce IL-6 production in renal cell carcinoma cells 
in vivo. Future studies on the mechanism(s) leading 
to the IL-6 gene activation in renal cell carcinoma 
cells in vivo may clarify the oncogenesis of renal 
cell carcinoma. 
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